MARKET

BRNS

BRNS

Barinthus Biotherapeutics plc
NASDAQ
0.7400
+0.0607
+8.94%
After Hours: 0.7251 -0.0149 -2.01% 16:10 12/15 EST
OPEN
0.7300
PREV CLOSE
0.6793
HIGH
0.7400
LOW
0.6815
VOLUME
140.71K
TURNOVER
--
52 WEEK HIGH
2.920
52 WEEK LOW
0.6400
MARKET CAP
30.21M
P/E (TTM)
-0.3933
1D
5D
1M
3M
1Y
5Y
1D
Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Upgraded to Buy: What Does It Mean for the Stock?
NASDAQ · 6h ago
Weekly Report: what happened at BRNS last week (1208-1212)?
Weekly Report · 13h ago
Promising Clinical Trial Results and Strategic Merger Drive Buy Rating for Barinthus Biotherapeutics
TipRanks · 4d ago
Barinthus Biotherapeutics Updates on AVALON Trial Progress
TipRanks · 5d ago
Barinthus Biotherapeutics announces update on Phase 1 trial of VTP-1000
TipRanks · 5d ago
Barinthus Bio Issues Update On First-In-Human Phase 1 Trial Of VTP-1000 In Adults With Celiac Disease
Benzinga · 5d ago
Weekly Report: what happened at BRNS last week (1201-1205)?
Weekly Report · 12/08 10:11
Weekly Report: what happened at BRNS last week (1124-1128)?
Weekly Report · 12/01 10:07
More
About BRNS
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.

Webull offers Barinthus Biotherapeutics PLC - ADR stock information, including NASDAQ: BRNS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BRNS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BRNS stock methods without spending real money on the virtual paper trading platform.